HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation

Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART

(2010) Barbara Ensoli et al.   PLoS One

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy

(2009) Radjin Steingrover et al.   AIDS

Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification

(2009) Zabrina L. Brumme et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

(2009) A. R. Stacey et al.   JOURNAL OF VIROLOGY

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up

(2009) Olimpia Longo et al.   VACCINE

The preventive phase I trial with the HIV-1 Tat-based vaccine

(2009) Barbara Ensoli et al.   VACCINE

A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting

(2009) Gideon Goldstein et al.   VACCINE

Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease

(2008) Bita Sahaf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV rebounds from latently infected cells, rather than from continuing low-level replication

(2008) B. Joos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA